Which statement about acrolein is true in the context of chemotherapy-related bladder toxicity?

Which statement about acrolein is true in the context of chemotherapy-related bladder toxicity?

• A. Acrolein is a metabolite responsible for chemotherapy-induced urothelial toxicity
• B. Acrolein is a protective agent
• C. Acrolein is a benzene derivative
• D. Acrolein is an antiemetic

Answer: (A)

In this context, the harmful factor is acrolein, a metabolite produced when cyclophosphamide and ifosfamide are activated. It is excreted in the urine at high concentrations and irritates the bladder lining, leading to urothelial toxicity such as hemorrhagic cystitis. This explains why protective strategies like Mesna are used to bind acrolein in the urine and why adequate hydration helps reduce risk. Acrolein is not a protective agent, not a benzene derivative, and not an antiemetic.

In this context, the harmful factor is acrolein, a metabolite produced when cyclophosphamide and ifosfamide are activated. It is excreted in the urine at high concentrations and irritates the bladder lining, leading to urothelial toxicity such as hemorrhagic cystitis. This explains why protective strategies like Mesna are used to bind acrolein in the urine and why adequate hydration helps reduce risk. Acrolein is not a protective agent, not a benzene derivative, and not an antiemetic.